The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women

AIDS
Stein SchalkwijkPANNA Network

Abstract

To describe the pharmacokinetics of abacavir 600 mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum. A nonrandomized, open-label, multicentre, phase-IV study. HIV-positive pregnant women receiving abacavir 600 mg q.d. as part of clinical care were included. Intensive 24-h pharmacokinetic sampling was performed during the third trimester and at least 2 weeks after delivery. Pharmacokinetic parameters were calculated by noncompartmental analysis. Paired cord blood and maternal blood samples were taken at delivery when feasible. A total of 14 women were included in the analysis. Geometric mean ratios (90% confidence intervals) of third trimester versus postpartum were 1.05 (0.92-1.19) for AUC0-24h and 1.00 (0.83-1.21) for Cmax. The median (range) ratio of abacavir cord plasma to maternal plasma was 1.0 (0.7-1.0, n = 3). Viral load at the third trimester visit was less than 50 copies/ml in 13 participants (93%; one unknown). In total, 13 (93%; one unknown) children were tested HIV-negative. The pharmacokinetics of abacavir 600 mg q.d. during pregnancy are equivalent to postpartum. No dose adjustments are required during pregnancy and similar antiviral activity is expected.

References

May 1, 1997·Antimicrobial Agents and Chemotherapy·S M DalugeT A Krenitsky
Feb 14, 2006·AIDS·Brookie M BestUNKNOWN PACTG P1026s Study Team
May 16, 2008·Clinical Pharmacokinetics·Geoffrey J YuenGary E Pakes
Jul 30, 2014·Antimicrobial Agents and Chemotherapy·Floris FauchetDéborah Hirt
Sep 17, 2014·Clinical Pharmacokinetics·Shelley A McCormack, Brookie M Best
Oct 19, 2014·The Journal of Antimicrobial Chemotherapy·Angela ColbersUNKNOWN PANNA Network
Dec 4, 2014·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Vani VannappagariConway Gee
Aug 25, 2015·Pharmacotherapy·Elise M GilbertMilena M McLaughlin

❮ Previous
Next ❯

Citations

Jun 9, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stein SchalkwijkUNKNOWN Pharmacokinetics of newly developed antiretroviral agents in HIV-infected pregnant women (PANNA) Network
Sep 19, 2019·Journal of the International AIDS Society·Lee FairlieMatthew Chersich
Jun 28, 2020·Journal of Pharmacokinetics and Pharmacodynamics·Khaled Abduljalil, Raj K Singh Badhan

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00825929

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Angela ColbersPANNA Network and the IMPAACT 1026 Study Team
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Maren BlonkPANNA Network
Journal of Acquired Immune Deficiency Syndromes : JAIDS
Alice StekMark Mirochnick
© 2021 Meta ULC. All rights reserved